This was possibly explained by our previous study indicating that regorafenib potentiates immune-mediated HCC cell death by promoting mMICA expression to a greater extent than sorafenib, by mainly targeting ADAM9 [15]. This evidence concerns the gene ADAM9 and hepatocellular carcinoma.